University of Bielefeld Report issue

Academic/Hospital Phase 3
Founded: Bielefeld Germany (1869)

Organization Overview

First Clinical Trial
2018
NCT03444324
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Bielefeld University | Franziskus Hospital, Bielefeld | University of Bielefeld

Active Ingredients

Drugs in Phase 3 Trials (2)

blood plasma (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Coagulation Disorders (Phase 3)

Hemostatic Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2